UNSPSC 51383513: Ketorolac + homatropine methyl bromide

Treatment of pain and as antispasmodic: Containing Ketorolac and Homatropine Methylbromide is indicated for the short-term management of colic and spasms accompanied by severe to moderate pain present in cases of: Colic and spasms of gastrointestinal motility: intestinal and gastrointestinal colic, irritable bowel and spastic diarrhea. Colic and spasms of the biliary tract: vesicular gallstones, cholelithiasis, choledocholithiasis and cholecystitis. Colic and spasms of the urinary tract: Kidney colic, cystitis, tenesmus, dysmenorrhea, premenstrual tension.

UNSPSC 51383513 Ketorolac + homatropine methyl bromide is a Commodity code that in recent state and local procurement activity does not reflect purchases of this specific pharmaceutical combination. The recent solicitations tagged under this code involve naloxone, generic multi-source pharmaceuticals, and over-the-counter products procured through competitive bidding and cooperative purchasing frameworks, which fall outside the narrow scope of the code's stated product. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that acquire pharmaceuticals to support community health initiatives, emergency response programs, and state employee health plans. Vendors must meet federal and state compliance requirements including FDA certification, Drug Supply Chain Security Act adherence, current Good Manufacturing Practices, workers' compensation and liability insurance, E-Verify enrollment, and drug-free workplace certification.

Geographic activity centers on Florida and Minnesota, with broader multistate reach through cooperative purchasing vehicles. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon through authorized wholesalers. The code shows little relevant recent activity aligned to its nominal product specification; the mismatch between the code's stated pharmaceutical and the actual procurements suggests potential miscoding or category drift in the tagging process.